TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial
Brief Summary: Remission of ANCA-associated vasculitis can be obtained in approximately 80% of the patients with a combination of corticosteroids and cyclophosphamide. However, relapses are frequent. This point warrants the prescription of a maintenance treatment with a less toxic immunosuppressant for several months to years. The optimal drug in this indication is not determine. We decided therefore to compare the 2 most used drugs in this indication. Induction therapy consists in the combination of corticosteroids and intravenous cyclophosphamide pulses. Corticotherapy consisted first in one daily methylprednisolone pulse, for 1 to 3 days, followed by oral prednisolone at the dose of 1 mg/kg/d for 3 weeks, then progressively tapered and stopped at the 18th month from the diagnosis. Cyclophosphamide is administered every 2 weeks for the first 3 bolus (0.6 g/m2 - D1, 15 and 30), then every 3 weeks (0.7 g/m2). Once remission is achieved, patients receive 3 additional bolus (0.7 g/m2). At that time, patients are randomized for a maintenance treatment with azathioprine (2 mg/kg/d, orally) or oral methotrexate (starting at the dose of 0.3 mg/kg/wk, then progressively increased every weeks by 2.5mg, if necessary, to a maximum and optimal dose of 25 mg/wk) for 12 months.


Options:
A: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Intravenous immunoglobulins (human immunoglobulins G); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Azathioprine: 2 mg/kg/day; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease
Brief Summary: Patients with Clostridium difficile associated disease who fulfill the eligibility criteria will be approached to participate. All study patients must receive standard of care treatment for Clostridium difficile associated disease. Enrolled patients will be randomized to receive a single intravenous solution of a human monoclonal antibody (huMab) to C. difficile toxin A (GS-CDA1) combined with a human monoclonal antibody to C. difficile toxin B (MDX-1388) or 0.9% sodium chloride as placebo in a 1:1 treatment allocation. Patients will be evaluated for safety and clinical outcomes through day 84 +/- 10 days. Occurrence of adverse events, use of concomitant medications, and stool output will be assessed at scheduled phone contacts and study visits. Some patients enrolled will have a subsequent visit on day 168 ± 14 days.


Options:
A: Arm Label: GS-CDA1/MDX-1388; Type: EXPERIMENTAL; Interventions: Biological: GS-CDA1/MDX-1388 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: normal saline | Intervention Type: BIOLOGICAL; Name: GS-CDA1/MDX-1388; Assigned to Arm(s): GS-CDA1/MDX-1388 | Intervention Type: BIOLOGICAL; Name: normal saline; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: tolevamer potassium-sodium (GT267-004); Assigned to Arm(s): N/A
C: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
D: Arm Label: CB-183,315, 125 mg; Type: EXPERIMENTAL; Interventions: Drug: CB-183,315, Drug: Placebo | Arm Label: CB-183,315, 250 mg; Type: EXPERIMENTAL; Interventions: Drug: CB-183,315, Drug: Placebo | Arm Label: Vancomycin, 125 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: CB-183,315; Assigned to Arm(s): CB-183,315, 125 mg, CB-183,315, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CB-183,315, 125 mg, CB-183,315, 250 mg | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Vancomycin, 125 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Non-Gestational Acute Uterine BleedingComparing Oral Medroxyprogesterone Acetate and Monophasic Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol
Brief Summary: To determine the relative efficacy of multidose medroxyprogesterone acetate (MPA, Provera) and a multidose, monophasic combination oral contraceptive in the treatment of hemodynamically stable women with non-gestational, acute uterine bleeding.


Options:
A: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Provera; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination Birth Control pills; Assigned to Arm(s): N/A
C: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computer-Based Training in Cognitive Behavior Therapy
Brief Summary: The computer-based training program (CBT for CBT) focuses on teaching basic coping skills, presenting examples of effective use of coping skills in a number of realistic situations in video form, and providing opportunities for patients to practice and review new skills while receiving substance abuse treatment.


Options:
A: Arm Label: Standard treatment Alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: standard treatment | Arm Label: ST+CM; Type: EXPERIMENTAL; Interventions: Behavioral: ST+CM | Intervention Type: BEHAVIORAL; Name: ST+CM; Assigned to Arm(s): ST+CM | Intervention Type: BEHAVIORAL; Name: standard treatment; Assigned to Arm(s): Standard treatment Alone
B: Intervention Type: BEHAVIORAL; Name: contingency management and behavioral day treatment; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual (TAU) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Treatment as usual (TAU), Behavioral: CBT for CBT | Intervention Type: OTHER; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: CBT for CBT; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Disulfiram; Type: ACTIVE_COMPARATOR; Interventions: Drug: disulfiram | Arm Label: Placebo plus Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo plus Contingency Management | Arm Label: Disulfiram plus Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Disulfiram plus Contingency Management | Intervention Type: DRUG; Name: disulfiram; Assigned to Arm(s): Disulfiram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Placebo plus Contingency Management; Assigned to Arm(s): Placebo plus Contingency Management | Intervention Type: DRUG; Name: Disulfiram plus Contingency Management; Assigned to Arm(s): Disulfiram plus Contingency Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computer-Based Training in Cognitive Behavior Therapy
Brief Summary: The computer-based training program (CBT for CBT) focuses on teaching basic coping skills, presenting examples of effective use of coping skills in a number of realistic situations in video form, and providing opportunities for patients to practice and review new skills while receiving substance abuse treatment.


Options:
A: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard Care | Arm Label: Contingency management for abstinence from drugs; Type: EXPERIMENTAL; Interventions: Behavioral: contingency management | Intervention Type: BEHAVIORAL; Name: contingency management; Assigned to Arm(s): Contingency management for abstinence from drugs | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
B: Arm Label: Standard; Type: OTHER; Interventions: Behavioral: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing | Arm Label: SI/WWE; Type: EXPERIMENTAL; Interventions: Behavioral: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing, Behavioral: Standard Intervention plus Well-Woman Exam | Arm Label: SI/WWE/PD; Type: EXPERIMENTAL; Interventions: Behavioral: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing, Behavioral: Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention | Intervention Type: BEHAVIORAL; Name: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing; Assigned to Arm(s): SI/WWE, SI/WWE/PD, Standard | Intervention Type: BEHAVIORAL; Name: Standard Intervention plus Well-Woman Exam; Assigned to Arm(s): SI/WWE | Intervention Type: BEHAVIORAL; Name: Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention; Assigned to Arm(s): SI/WWE/PD
C: Arm Label: Employment Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Employment Only | Arm Label: Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency management | Intervention Type: BEHAVIORAL; Name: Contingency management; Assigned to Arm(s): Contingency Management | Intervention Type: BEHAVIORAL; Name: Employment Only; Assigned to Arm(s): Employment Only
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual (TAU) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Treatment as usual (TAU), Behavioral: CBT for CBT | Intervention Type: OTHER; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: CBT for CBT; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension
Brief Summary: A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.


Options:
A: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: tolterodine | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group | Intervention Type: DRUG; Name: tolterodine; Assigned to Arm(s): tolterodine group
B: Arm Label: Oxybutynin topical gel; Type: EXPERIMENTAL; Interventions: Drug: Oxybutynin topical gel | Arm Label: Placebo topical gel; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo topical gel | Intervention Type: DRUG; Name: Oxybutynin topical gel; Assigned to Arm(s): Oxybutynin topical gel | Intervention Type: OTHER; Name: Placebo topical gel; Assigned to Arm(s): Placebo topical gel
C: Intervention Type: DRUG; Name: Tolterodine ER 4mg QD; Assigned to Arm(s): N/A
D: Arm Label: BOTOX®; Type: EXPERIMENTAL; Interventions: Biological: BOTOX®, Drug: solifenacin placebo | Arm Label: solifenacin; Type: ACTIVE_COMPARATOR; Interventions: Biological: BOTOX®, Drug: solifenacin, Drug: Botox placebo (normal saline) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: BOTOX®, Drug: Botox placebo (normal saline), Drug: solifenacin placebo | Intervention Type: BIOLOGICAL; Name: BOTOX®; Assigned to Arm(s): BOTOX®, placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): solifenacin | Intervention Type: DRUG; Name: Botox placebo (normal saline); Assigned to Arm(s): placebo, solifenacin | Intervention Type: DRUG; Name: solifenacin placebo; Assigned to Arm(s): BOTOX®, placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Brief Summary: Comparison of efficacy and toxicity of the combination treatment of deferiprone and desferrioxamine with the single agent treatment of either drug


Options:
A: Arm Label: Deferiprone; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): Deferiprone | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferoxamine
B: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
C: Arm Label: Deferiprone + Desferrioxamine; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1), Drug: Desferrioxamine | Arm Label: Deferiprone single agent; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1) | Arm Label: Desferrioxamine single agent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desferrioxamine | Intervention Type: DRUG; Name: Deferiprone (L1); Assigned to Arm(s): Deferiprone + Desferrioxamine, Deferiprone single agent | Intervention Type: DRUG; Name: Desferrioxamine; Assigned to Arm(s): Deferiprone + Desferrioxamine, Desferrioxamine single agent
D: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Brief Summary: Comparison of efficacy and toxicity of the combination treatment of deferiprone and desferrioxamine with the single agent treatment of either drug


Options:
A: Intervention Type: DRUG; Name: deferiprone; Assigned to Arm(s): N/A
B: Arm Label: Deferiprone + Desferrioxamine; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1), Drug: Desferrioxamine | Arm Label: Deferiprone single agent; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1) | Arm Label: Desferrioxamine single agent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desferrioxamine | Intervention Type: DRUG; Name: Deferiprone (L1); Assigned to Arm(s): Deferiprone + Desferrioxamine, Deferiprone single agent | Intervention Type: DRUG; Name: Desferrioxamine; Assigned to Arm(s): Deferiprone + Desferrioxamine, Desferrioxamine single agent
C: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Prospective Randomized Double Blind Trial of Bone Marrow Mononuclear Cells Transplantation Through Intracoronary Injection in Patients With Acute Myocardial Infarction.
Brief Summary: The purpose of this study is to determine cell therapy efficacy in patients with ST elevation acute myocardial infarction (STEMI)


Options:
A: Arm Label: SC Group; Type: EXPERIMENTAL; Interventions: Biological: CD34+ autologous stem cell transplantation, Drug: Bone Marrow Stimulation, Biological: SC therapy | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: CD34+ autologous stem cell transplantation; Assigned to Arm(s): SC Group | Intervention Type: DRUG; Name: Bone Marrow Stimulation; Assigned to Arm(s): SC Group | Intervention Type: BIOLOGICAL; Name: SC therapy; Assigned to Arm(s): SC Group
B: Arm Label: Stem Cell therapy; Type: EXPERIMENTAL; Interventions: Procedure: Stem cell, Drug: Filgrastime (G-CSF) | Arm Label: Standart therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standart therapy | Intervention Type: PROCEDURE; Name: Stem cell; Assigned to Arm(s): Stem Cell therapy | Intervention Type: DRUG; Name: Filgrastime (G-CSF); Assigned to Arm(s): Stem Cell therapy | Intervention Type: DRUG; Name: Standart therapy; Assigned to Arm(s): Standart therapy
C: Arm Label: MPC Intramyocardial Injection; Type: EXPERIMENTAL; Interventions: Biological: MPC Intramyocardial Injection | Arm Label: Control Solution; Type: SHAM_COMPARATOR; Interventions: Drug: Control Solution | Intervention Type: BIOLOGICAL; Name: MPC Intramyocardial Injection; Assigned to Arm(s): MPC Intramyocardial Injection | Intervention Type: DRUG; Name: Control Solution; Assigned to Arm(s): Control Solution
D: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Prospective Randomized Double Blind Trial of Bone Marrow Mononuclear Cells Transplantation Through Intracoronary Injection in Patients With Acute Myocardial Infarction.
Brief Summary: The purpose of this study is to determine cell therapy efficacy in patients with ST elevation acute myocardial infarction (STEMI)


Options:
A: Arm Label: Provacel: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Provacel; Assigned to Arm(s): Provacel: Cohort 1, Provacel: Cohort 2, Provacel: Cohort 3, Provacel: Cohort 4 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: G-CSF with/without darbepoetin, peripheral blood stem cell infusion; Assigned to Arm(s): N/A
C: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Arm Label: Late; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Intervention Type: PROCEDURE; Name: intracoronary bone marrow cells infusion; Assigned to Arm(s): Early, Late

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maximizing the Efficacy of Cognitive Behavioral Therapy With Medication and Contingency Management
Brief Summary: This is a study of four treatments for chronic cocaine use and may help study participants to control their drug use. All participants will receive weekly individual cognitive behavioral therapy (CBT).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Disulfiram; Type: ACTIVE_COMPARATOR; Interventions: Drug: disulfiram | Arm Label: Placebo plus Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo plus Contingency Management | Arm Label: Disulfiram plus Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Disulfiram plus Contingency Management | Intervention Type: DRUG; Name: disulfiram; Assigned to Arm(s): Disulfiram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Placebo plus Contingency Management; Assigned to Arm(s): Placebo plus Contingency Management | Intervention Type: DRUG; Name: Disulfiram plus Contingency Management; Assigned to Arm(s): Disulfiram plus Contingency Management
B: Arm Label: Standard treatment Alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: standard treatment | Arm Label: ST+CM; Type: EXPERIMENTAL; Interventions: Behavioral: ST+CM | Intervention Type: BEHAVIORAL; Name: ST+CM; Assigned to Arm(s): ST+CM | Intervention Type: BEHAVIORAL; Name: standard treatment; Assigned to Arm(s): Standard treatment Alone
C: Arm Label: Referral to community resources; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency management | Intervention Type: BEHAVIORAL; Name: Contingency management; Assigned to Arm(s): Contingency Management
D: Arm Label: ARTEMIS+CM; Type: EXPERIMENTAL; Interventions: Behavioral: Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS), Behavioral: Contingency Management (CM) | Arm Label: Attention-Control+CM; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Contingency Management (CM) | Intervention Type: BEHAVIORAL; Name: Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS); Assigned to Arm(s): ARTEMIS+CM | Intervention Type: BEHAVIORAL; Name: Contingency Management (CM); Assigned to Arm(s): ARTEMIS+CM, Attention-Control+CM

Answer: A